Impact of Multivessel Coronary Artery Disease on Long Term Prognosis in Patients with ST-segment Elevation Myocardial Infarction

Open access


Background: A significant proportion of patients with ST-segment elevation myocardial infarction (STEMI) have multivessel coronary artery disease (MVD), and they are at high risk for recurrent cardiac events. The aim of the present study was to analyze the impact of MVD on long-term cardiovascular mortality in STEMI patients treated with primary percutaneous coronary intervention (pPCI). Method: This study included 3,115 consecutive STEMI patients hospitalized in the Coronary Care Unit of the Clinical Centre of Serbia, between November 2005 and January 2012. Patients were divided in two groups: MVD and no MVD. MVD disease was defined as stenosis greater than 50% by visual assessment in more than one major coronary artery. Primary PCI was limited to the infarct-related artery (IRA). Cardiovascular mortality was defined as any death from cardiovascular reason (myocardial reinfarction, low-output heart failure, and sudden death). Patients presenting with cardiogenic shock were excluded. Patients were followed-up for 6 years after enrollment. Results: Among 3,115 analyzed patients, 1,352 (43.4%) patients had no MVD and 1,763 (56.6%) had MVD; among patients with MVD, 926 (52.6%) had two-vessel disease and 837 (47.4%) had three-vessel disease. Compared with patients with single-vessel disease, patients with MVD were older, had longer pain duration, and presented more often with heart failure; they were more likely to have previous coronary artery disease, diabetes, hypertension, and chronic kidney disease; post-procedural flow TIMI <3 was more frequently observed in patients with MVD than in patients with no MVD (5.9% vs. 3.1%, p <0.001). Patients with MVD had lower left ventricular ejection fraction than patients with single-vessel disease: 45% (interquartile range [IQR] 40¬–55%) vs. 50% (IQR 43–55%), p <0.001. Revascularization of non-IRA lesions was performed at index hospitalization in 1,075 (61%) patients, and in 602 (34.1%) patients revascularization was performed in the first few months after pPCI (median 1.5 months, IQR 1–2.5 months); coronary artery bypass grafting was performed in 291 (18.4%) patients and PCI (with stent implantation) in 1,368 (81.6%) patients. Six-year cardiovascular mortality was significantly higher in patients with MVD than in patients with single-vessel disease (10.4% vs. 4.6%, p <0.001). In multivariate Cox regression analysis, MVD remained an independent predictor for 6-year cardiovascular mortality (HR 1.55, 95% CI 1.11–2.06, p = 0.041). Conclusion: In STEMI patients treated with pPCI, the presence of MVD remained an independent predictor for higher long-term cardiovascular mortality despite early revascularization of the remaining stenosis in non-IRA.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. De Waha S Eitel I Desch S et al. Impact of multivessel coronary artery disease on reperfusion success in patients with ST elevation myocardial infarction: A substudy of the AIDA STEMI trial. Eur Heart J Acute Cardiovascular Care. 2018;7:28-37. doi: 10.1177/2048872615624240.

  • 2. Lekston A Tajstra M Gąsior et al. Impact of multivessel coronary disease on one-year mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. Kardiol Pol. 2011;69:336-343.

  • 3. Batra MK Rasool SI Solangi BA et al. Multivessel disease as a prognostic marker in patients presenting for primary percutaneous coronary intervention. J Ayub Med Coll Abbottabad. 2018;30:534-538.

  • 4. De Luca G Gibson M Cutlip D et al. Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors. Arch Cardiovasc Dis. 2013;106:155-161. doi: 10.1016/j.acvd.2012.12.007.

  • 5. Park DW Clare RM Schulte PJ et al. Extent location and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014;312:2019-2027. doi: 10.1001/jama.2014.15095.

  • 6. Tarantini G Napodano M Gasparetto N et al. Impact of multivessel coronary artery disease on early ischemic injury late clinical outcome and remodeling in patients with acute myocardial infarction treated by primary coronary angioplasty. Coron Artery Dis. 2010;21:78-86. doi: 10.1097/MCA.0b013e328335a074.

  • 7. De Luca G Parodi G Sciagrà R et al. Impact of multivessel disease on infarct size among STEMI patients undergoing primary angioplasty. Atherosclerosis. 2014;234:244-248. doi:

  • 8. Widimsky P Holmes DR Jr. How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease? Eur Heart J. 2011;32:396-403. doi: 10.1093/eurheartj/ehq410.

  • 9. Greshlick AH Khan JN Kelly DJ et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease. J Am Coll Cardiol. 2015;65:963-972. doi: 10.1016/j.jacc.2014.12.038.

  • 10. Neumann FJ Sousa-Uva M Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2019;40:87-165. doi:

  • 11. Mrdovic I Savic L Lasica R et al. Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register. Eur Heart J Acute Cardiovascular Care. 2014;3:56-66. doi: 10.1177/2048872613514013.

  • 12. Sorajja P Gersh BJ Cox DA et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28:1709-1716. doi: 10.1093/eurheartj/ehm184.

  • 13. Wald DS Morris JK Wald NJ et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369:1115-1123. doi: 10.1056/NEJMoa1305520.

Journal information
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 83 83 20
PDF Downloads 52 52 5